Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $132.00 short put and a strike $127.00 long put offers a potential 37.36% return on risk over the next 32 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $132.00 by expiration. The full premium credit of $1.36 would be kept by the premium seller. The risk of $3.64 would be incurred if the stock dropped below the $127.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 57.48 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Announcement of top-line results from Phase 3 FOCUS Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed and advanced refractory multiple myeloma(81.8KB)
Wed, 20 Aug 2014 07:33:14 GMT
noodls – … This is an abstract of the original noodl. To continue reading this document, click here for the original version.
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416
Tue, 19 Aug 2014 20:25:02 GMT
A New Cannabinoid-based Arthritis Therapy in the Making
Tue, 19 Aug 2014 13:50:00 GMT
Accesswire – WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based …
Amgen Names Elliott M. Levy, M.D., Senior Vice President, Global Development
Tue, 19 Aug 2014 13:40:45 GMT
noodls – THOUSAND OAKS, Calif. (Aug. 19, 2014) – Amgen (NASDAQ:AMGN) today announced that Elliott M. Levy, M.D., has been named senior vice president, Global Development, effective Sept. 8, 2014. Levy comes to …
Hot biotech drugs
Tue, 19 Aug 2014 11:07:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook